DelMar Announces Relocation of Company Headquarters to San Diego

Jul 10, 2019

Delmar Pharmaceuticals Announces Termination Of Rights Offering

Jun 27, 2019

DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019

Jun 25, 2019

Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering

Jun 11, 2019

DelMar Pharmaceuticals Announces Closing of Financing

Jun 5, 2019

DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 3, 2019

DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering

Jun 3, 2019

DelMar Pharmaceuticals Updates Key Dates of Rights Offering

May 29, 2019

DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board

May 20, 2019

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results

May 15, 2019